AKR1C3 and prostate cancer: Meta-analysis of seven prostate cancer datasets that included normal prostate or primary prostate carcinoma samples in addition to CRPC revealed that AKR1C3 expression is significantly upregulated in CRPC relative to both normal prostate and primary prostate carcinoma (P < 0.001; one-way ANOVA with Dunnett’s multiple comparison analysis; Figure 2A).